The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending marketing authorization for Ascendis Pharma's once-weekly TransCon CNP (navepegritide). The recommendation covers treatment for achondroplasia in children aged two and older with open epiphyses. This decision follows a review of clinical data from three randomized, double-blind, placebo-controlled trials and up to three years of open-label extension data. The final European Commission decision is expected during the fourth quarter of 2026. If authorized, Ascendis expects its first EU launch under the brand name YUVIWEL in Germany during the first quarter of 2027. Ascendis Pharma A/S operates as a biopharmaceutical company focused on developing therapies for rare diseases.
